#USA #Ewing #GS1 US #Drug Supply Chain #Pharmaceutical Returns

Introduction

In a recent announcement, GS1 US introduced an essential resource titled "Best Practice Guidance for the Handling of Saleable Return Transactions." This document aims to streamline the return process of pharmaceutical products, particularly addressing the complexities that arise when dealing with returnable prescription drugs. With the guidance, GS1 US hopes to provide industry stakeholders with a standardized approach to handle saleable returns, which is crucial for compliance with the Drug Supply Chain Security Act (DSCSA).

Context and Importance of the Guidance

Handling returns in the pharmaceutical sector has always posed challenges, especially with the requirements dictated by the DSCSA. This act mandates that any returned prescription drug meant for resale must have its product identifier verified and associated with the relevant Transaction Information (TI) and Transaction Statement (TS) before it can be reintroduced into commercial circulation. The new guidance from GS1 US outlines a framework that will help manufacturers, wholesalers, pharmacies, hospitals, and other authorized partners manage these processes effectively.

The guidance serves as a roadmap by providing best practices across various stages of the return process. Specifically, it addresses key areas such as return authorization, product verification, documentation, and exception management. These practices are invaluable for ensuring the integrity of product handling and compliance with regulatory standards.

Key Features of the Guidance

1. Common Framework

GS1 US emphasizes the need for a shared understanding among trading partners regarding how to verify returns and resolve discrepancies. This common framework is crucial in fostering collaboration across the supply chain and improving operational efficiency.

2. Comprehensive Best Practices

The guidance goes into detail on recommended practices for various aspects of saleable returns, including:

• - Return Authorization: Protocols that need to be established to approve returns before they are physically processed.
• - Product Verification: Techniques to confirm that returned products match the associated transaction records.
• - Exceptional Case Handling: Strategies for managing unique scenarios that may not fit typical return processes.
• - Recordkeeping: Importance of maintaining meticulous records to support compliance with DSCSA requirements.

3. Incorporation of GS1 Standards

To enhance clarity and operational efficiency, the guidance integrates GS1 standards that are already in use across the industry, including Global Trade Item Numbers (GTINs) and Global Location Numbers (GLNs). These standards facilitate consistent product identification and data exchange, enabling a smoother return process.

Industry Reactions

Tracy Nasarenko, the Vice President of Community Engagement at GS1 US, remarked on the challenges of misalignment between product identifiers and transaction records in the return process. She stated, "Saleable returns can create operational and compliance challenges when product, serialized identifiers, and transaction records do not align. This guidance gives trading partners a common approach for verifying returned products, identifying and resolving exceptions, and maintaining the records needed to support DSCSA requirements. Greater consistency across the industry can help trading partners make return decisions more efficiently and with greater confidence."

Conclusion

The launch of the Best Practice Guidance for the Handling of Saleable Return Transactions by GS1 US represents a significant milestone in the pharmaceutical industry’s quest for efficiency and compliance. By following these recommended practices, trading partners can not only enhance their operational capabilities but also ensure the integrity of the pharmaceuticals being reintroduced into the market. Those interested in this critical resource can download the guidance directly from GS1 US’s website.

For more insight into pharmaceutical supply chain visibility and management, individuals and companies can explore the GS1 Standards documentation and related DSCSA resources through their dedicated resource page. As the industry navigates increasing complexities in drug returns, resources like these from GS1 US are now more important than ever.